Tallac Therapeutics is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer. Tallac’s pipeline of immunotherapy candidates are derived from the company’s novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) for targeted immune activation via systemic administration. Several TRAAC molecules are in various stages of discovery and preclinical development.
Location: United States, California, Burlingame
Employees: 11-50
Total raised: $77M
Founded date: 2018
Investors 2
| Date | Name | Website |
| - | MRL Ventur... | mrlv.com |
| 16.07.2020 | Lightstone... | lightstone... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.08.2023 | - | $15M | - |
| 01.12.2020 | Series A | $62M | Matrix Par... |
Mentions in press and media 7
| Date | Title | Description |
| 03.08.2023 | Tallac Therapeutics Receives $15M Venture Loan Facility | Tallac Therapeutics, Inc., a Burlingame, CA-based developer of multiple novel immunotherapies to fight cancer, received a $15m venture loan facility. Horizon Technology Finance Corporation (NASDAQ: HRZN) provided the financing. A sum of $5m... |
| 02.12.2020 | Daily funding roundup - Dec. 1st, 2020 | WaveOne has raised $6.5M; Databand landed $14.5M; Proscia has secured $23M Reposite: Reposite is a New York-based maker of a database that helps travel agents manage suppliers and clients, track proposals. Reposite and better manage their b... |
| 02.12.2020 | Tallac raises $62M in Series A to advance novel cancer immunotherapies | - |
| 01.12.2020 | Tallac Therapeutics Raises $62M in Series A Financing | Tallac Therapeutics, Inc., a Burlingame, Calif.-based biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, raised $62m in Series A financing. Backers included venBio Partners, Morningside Venture, ... |
| 01.12.2020 | Tallac Therapeutics launches with $62M run by ALX Oncology vets, with an eye on next-gen cancer | A host of top-suite venture capitalist firms has helped put together a meaty series A for an immuno-oncology biotech 2.0. Californian startup Tallac Therapeutics has $62 million and the backing of venBio Partners, Morningside Venture, Light... |
| 01.12.2020 | Tallac Therapeutics launches with $62M run by ALX Oncology vets, with an eye on next-gen cancer W h i t e p a p e r Weighing the Costs: | A host of top-suite venture capitalist firms has helped put together a meaty series A for an immuno-oncology biotech 2.0. Sponsored by Agilent Technologies How would you like to win free bench space at Lab Central for one scientist for an e... |
| - | Tallac Therapeutics | “Tallac Therapeutics, Inc – Landing page” |